Home›Trial›NCT06744335
NCT06744335Completed

Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)

Study Summary

Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan

Conditions
Rate of CKD Diagnosis in Patients With AH and CKD MarkersDemographic and Clinical Characteristics for Those PatientsRoutine Therapy Before and After the Diagnosis of CKD
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
AZN
AstraZeneca
Oncology/Respiratory
C51/100
Study Details
Enrollment1283 participants
Primary Completion2026-08-20
Lead SponsorAstraZeneca
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

Primary completion: 2026-08-20
Enrolled: 1,283 participants
Sponsor Catalyst Profile

AstraZeneca (AZN) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

AZN Full Pipeline →All Companies →
Other Trials from AstraZeneca
NCT02511106AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcin…(PHASE3)NCT06346392AZD0901 Compared With Investigator's Choice of Therapy in Participants With Seco…(PHASE3)NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participa…(PHASE3)NCT03459846A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Inelig…(PHASE2)NCT05048797A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the …(PHASE3)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence